Mifepristone Shown to Reduce A1C in Patients with Difficult-to-Control Type 2 Diabetes and Hypercortisolism

Mifepristone Shown to Reduce A1C in Patients with Difficult-to-Control Type 2 Diabetes and Hypercortisolism

Study Results Signal Paradigm Shift in Diabetes Care for Patients with Difficult-to-Control Type 2 Diabetes

Mifepristone Helped Control Diabetes in Those With Hypercortisolism

(MedPage Today) -- CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and hypercortisolism, a randomized placebo-controlled trial showed. Among 136 patients, the least squares mean...

Mifepristone improves glucose control in patients with type 2 diabetes, hypercortisolism

CHICAGO — In patients with hypercortisolism and inadequately controlled type 2 diabetes, mifepristone lowered HbA1c levels by about 1.5% over 24 weeks compared with placebo, according to the final results of the CATALYST trial. As Healio previously reported, in part one of the CATALYST trial, researchers determined that the prevalence of hypercortisolism was 24% in a cohort of

CATALYST Trial: Mifepristone Improves Glycemic Control in Type 2 Diabetes with Hypercortisolism

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.